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OBJECTIVES We sought to determine the prevalence and phenotype of beta-myosin heavy chain gene MYH7
mutations in a large cohort of unrelated patients with hypertrophic cardiomyopathy (HCM).
BACKGROUND Hypertrophic cardiomyopathy is a heterogeneous cardiac disease. MYH7 mutations are one of
the most common genetic causes of HCM and have been associated with severe hypertrophy,
young age of diagnosis, and high risk of sudden cardiac death. However, these clinical
findings from large, family studies have not been confirmed in a large unrelated cohort.
METHODS Deoxyribonucleic (DNA) samples obtained from 389 HCM outpatients seen at this tertiary
referral center were analyzed for mutations, using polymerase chain reaction, denaturing
high-performance liquid chromatography, and DNA sequencing for all 38 protein-coding
exons of MYH7. Clinical data were extracted from patient records blinded to patient
genotype.
RESULTS Fifty-eight patients (15%) harbored 40 different mutations in MYH7. Compared with HCM
patients without MYH7 mutations, HCM patients with MYH7 were younger at diagnosis (32.9
vs. 42.7 years, p 0.0002), had more hypertrophy (left ventricular wall thickness of 24.2 vs. 21.1
mm, p  0.0009), and more frequently underwent myectomy (60% vs. 38%, p  0.002). The
HCM patients with MYH7 mutations more often had a family history of HCM (43% vs. 29%,
p 0.006), but there was no difference in family history of sudden death (16% vs. 14%, pNS).
CONCLUSIONS In this setting, HCM patients with MYH7 were diagnosed at a younger age and had more
hypertrophy, but they had no greater frequency of sudden death among first-degree relatives.
Although these associations may prove useful for targeted gene screening, caution should be
exercised in terms of using pathogenic status in risk stratification. (J Am Coll Cardiol 2004;
44:602–10) © 2004 by the American College of Cardiology Foundationp
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pypertrophic cardiomyopathy (HCM) is a complex genetic
isease that affects 1 in 500 persons and is the leading cause of
udden cardiac death (SCD) in youth (1–3). Prognosis and
reatment decisions are difficult because of the extreme heter-
geneity associated with HCM (4,5). The severity of the
isease varies from a life-long asymptomatic course to chronic,
rogressive heart failure or SCD at a young age. Mutations
ssociated with HCM are scattered throughout sarcomeric
enes, with mutations in the gene encoding the beta-myosin
eavy chain (MYH7), representing one of the most common
enetic causes of HCM (2,6,7). It is estimated that 30% of
ll cases of HCM are due specifically to MYH7 mutations
8–10). Over 80 missense mutations have been identified in
he globular head and neck domains of MYH7, encoded by
xons 3 through 23, in HCM individuals (11). Greater disease
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Manuscript received November 4, 2003; revised manuscript received March 18,r004, accepted April 13, 2004.enetrance, more severe hypertrophy, and high risk of SCD
ave been associated with mutations in MYH7 versus other
arcomeric genes (12).
These estimations of mutation frequency and genotype-
henotype correlations are based on pioneering linkage
tudies that, by necessity, selected patient groups with
xtensive family pedigrees (13,14). Recently, the first mo-
ecular genetic investigation of a sizeable cohort of unrelated
ndividuals with HCM (n 197) was reported (15). MYH7
utations were identified in 25% of these HCM patients
nd were the most common cause of “malignant” HCM.
owever, of the 40 families with a known prognosis, only
0 (25%) had experienced a “malignant” course. Further
nvestigation of larger cohorts having robust clinical data is
ecessary to elucidate the scope and significance of muta-
ions in MYH7. We determined the spectrum, prevalence,
nd phenotype of MYH7 mutations through comprehensive
utational analysis of 389 unrelated patients seen at our
CM Clinic. Mindful of the potential for referral bias,
atients were also compared across two groups: regional
atients (from Minnesota, Wisconsin, and Iowa) and non-
egional patients.
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linical characterization of unrelated HCM cases. In-
ormed, written consent was obtained in accordance with
tudy protocols approved by the Mayo Foundation Institu-
ional Review Board. Blood samples were obtained from
89 unrelated study participants (age at diagnosis 41.3 19
ears, 215 males) seen at the Mayo Medical Center’s HCM
utpatient Clinic in Rochester, Minnesota, between April
997 and December 2001, and confirmed to have unequiv-
cal and unexplained left ventricular hypertrophy. All clin-
cal variables were extracted from patient records blinded to
atient genotype and maintained in a customized database
or the HCM Clinic. Standard assessment of a family
istory excluded relatedness between study participants
hrough three degrees (i.e., first degree  offspring or
ibling; second degree grandchild, niece, or nephew; third
egree  great grandchild, cousin, and so on). When
elated individuals were identified within the cohort (n 
5), only the first individual who presented to this institu-
ion was included.
utational analysis. Purgene deoxyribonucleic acid (DNA)
xtraction kits (Gentra, Inc., Minneapolis, Minnesota) were
sed to obtain patient genomic DNA from peripheral blood
ymphocytes. Using forward and reverse primers designed in
ur laboratory, polymerase chain reaction (PCR) was per-
ormed for amplification of the genomic DNA (Table 1). Each
NA sample was analyzed for mutations in each of the 38
rotein-coding exons of MYH7. Denaturing high-
erformance liquid chromatography (DHPLC) methods were
ptimized for detection of sequence variations in each ampli-
on by the Transgenomic WAVE system (Omaha, Nebraska)
Table 1). Patient samples with abnormal DHPLC elution
rofiles were sequenced by automated dye terminator cycle
equencing using an ABI Prism 377 (Applied Biosystems,
oster City, California). Normal and abnormal chromato-
rams were compared to determine if sequence variations were
resent. All candidate mutations were confirmed by amplifi-
ation from stock DNA samples and direct sequencing to
xclude the possibility of random PCR-induced mutations or
ample contamination. To exclude novel nonsynonymous vari-
nts as common polymorphisms, DNA samples (Coriell Cell
epositories, Camden, New Jersey) from 100 African-
Abbreviations and Acronyms
DHPLC  denaturing high-performance liquid
chromatography
HCM  hypertrophic cardiomyopathy
ICD  implantable cardioverter-defibrillator
LVWT  left ventricular wall thickness
MYH7  beta-myosin heavy chain gene
PCR  polymerase chain reaction
SCD  sudden cardiac death
SNP  single-nucleotide polymorphismmerican and 100 Caucasian control subjects were analyzed.tandard nomenclature was employed for annotation at the
rotein level (16).
tatistical analysis. Differences between continuous vari-
bles were assessed using the unpaired t test. Chi-square
nalysis was used to analyze nominal variables. A p value
0.05 was considered statistically significant.
ESULTS
able 2 summarizes the clinical characteristics of the entire
ohort of unrelated HCM patients. At presentation to the
ayo Clinic, 216 (56%) of the 389 patients had cardiac
ymptoms. Approximately one-third (31%) had a family
istory of HCM involving a first-degree relative (parent,
ibling, or offspring), and 14% had a family history of
nexplained SCD involving a first-degree relative. The
ean maximal left ventricular wall thickness (LVWT) was
1.6 6 mm. Of the 389 patients, 161 underwent a surgical
yectomy (41%) and 60 had a cardioverter-defibrillator
mplanted (15%).
The patient population comprised 125 patients from the
egional area (Minnesota, Iowa, and Wisconsin residents)
nd 264 non-regional patients (Table 2). The patients from
he three-state region had significantly less left ventricular
utflow tract obstruction (39 40 mm Hg vs. 50 43 mm
g, p  0.02) and, hence, were less likely to have required
surgical myectomy (28% vs. 48%, p  0.01) than the
on-regional patients. For other parameters studied, includ-
ng family history of HCM or SCD, age at presentation,
nd LVWT, there was no significant difference between the
egional and non-regional populations.
From this cohort of 389 HCM patients, 58 (15%)
arbored MYH7 mutations, with over half (33 of 58)
ossessing a unique mutation (Table 3). Compared with
CM patients without MYH7 mutations, those with
YH7 were younger at the time of diagnosis (32.9 vs. 42.7
ears, p  0.0002), had more hypertrophy (LVWT of 24.1
s. 21.1 mm, p  0.0009), and more frequently had
ndergone a myectomy (60% vs. 38%, p  0.002). There
as also a higher frequency of a positive family history of
CM involving a first-degree relative (43% vs. 29%, p 
.006). However, there was no difference in family history
f SCD between patients with MYH7 mutations (16%) and
hose without MYH7 mutations (14%, p  NS).
We previously analyzed this cohort of 389 patients for
utations in the thin-filament genes (troponin T, troponin
, alpha-tropomyosin, and cardiac actin) (17). Compared
ith the 18 patients with thin-filament mutations, HCM
atients with MYH7 had more hypertrophy (LVWT of 24.1
8 mm vs. 19.8  6 mm, p  0.049) and a higher
ncidence of surgical myectomy (60% vs. 32%, p 0.02). In
ll other variables, including age at diagnosis, there were no
tatistically significant differences between HCM patients
aving either MYH7 (thick filament) or thin-filament genes
data not shown).When patients with MYH7 mutations from the regional
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as no significant difference in any variable studied, includ-
ng percentage with cardiac symptoms, LVWT, peak gra-
ient, and previous myectomy (Table 3).
Figure 1 depicts the spectrum of the mutations along the
ength of MYH7. Forty different mutations in MYH7 were
dentified. Nearly two-thirds (25 [63%] of 40) of these were
ovel, and none of these novel mutations were present in
00 reference alleles derived from 100 white and 100 black
ubjects. Of the 40 mutations, 39 were missense mutations.
he single exception was one patient with an in-frame
eletion of a lysine residue at position 847 (K847del).
In searching for MYH7 mutations, specific mutations
reviously ascribed as “malignant” or “benign” were identi-
ed. Three of 389 patients (1%) had a “malignant”
utation: R403Q, R453C, and G716R (9,12,18–20). All
able 1. Polymerase Chain Reaction Primer Sequences, Cycling
Exon
MgCl2
(mmol/l) PCR Method
Forwar
Seq
3 1.5 1 gggaaggg
4 1.5 1 aaccctctt
5 1.5 1 caactggc
6 1.5 1 gcagctcc
7 1.5 1 ctgatttga
8 1.5 1 cgcagaag
9 1.5 2 ggacttgg
10 2.0 1 ttgtgccca
11 1.5 3 cctccatga
12 2.0 1 tacccatca
13 2.0 2 acaggcat
14 2.0 2 gtgggatg
15 1.5 3 aggcacag
16 1.5 2 ttgaccata
17 2.0 1 cctccccac
18 1.5 1 tctggcatt
19 2.0 2 aatcagtga
20 1.5 1 gcagagca
21 1.5 1 ccccaccat
22 1.5 1 aggctcag
23 1.5 3 tgatgtgcc
24 1.5 1 agagcagc
25 1.5 1 gcctggctc
26 1.5 1 ccccaccag
27 1.5 1 agccgaga
28 1.5 1 ctccttcag
29 1.5 1 ggtgggga
30 1.5 1 gcaagggt
31 1.6 1 tgtccccat
32 1.5 1 tggggggc
33 1.5 1 aggcgtgt
34 1.5 1 tgtgccctg
35 1.5 1 tgcccactc
36 1.5 1 ctggggct
37 1.5 1 gctgggca
38 1.5 1 cggagggg
39 1.5 1 cccaagcc
40 1.5 1 ctgtccctg
CR method 1  94°C for 10 min; 40 cycles of 94°C for 30 s, 58°C for 30 s, and 72
0 s, 64°C for 20 s, and 72°C for 30 s; 35 cycles of 94°C for 20 s, 62°C for 20 s, and
or 30 s, 63°C for 30 s, and 72°C for 30 s; and 72°C for 10 min.
DHPLC  denaturing high-performance liquid chromatography; PCR  polymhree individuals were diagnosed with HCM at a young age R3 months, 16 years, and 24 years). However, there were 78
dditional patients diagnosed before age 25 years, who did
ot host one of these particular mutations. In addition, the
atient with R453C-MYH7 also had a second mutation
nvolving TNNT2.
Overall, 7 (1.8%) of 389 patients had a previously
ublished “benign” MYH7 mutation: 3 with R719Q and 4
ith L908V (9,21,22). All seven individuals had severe
isease, with five of seven having undergone septal myec-
omies, five requiring beta-blocker or calcium channel
locker therapy, four having a positive family history of
CD, and one receiving an orthotopic heart transplant as a
eenager for end-stage HCM with severe restrictive hemo-
ynamics. As a group, the average age at diagnosis was 24
7 years (range 3 months to 44 years), with four of the seven
ases being30 years old at diagnosis. One patient with the
ods, and DHPLC Temperatures
mer
e
Reverse Primer
Sequence
DHPLC
Temperature (°C)
tgggc ccagggtggactctcaca 63
aggag ggatggagcaagaacagag 63.5
ctgct ctatcccagttcccttcag 63.5
ttcc gatcagggagattctgaaag 57.5
ctggt aagaaggaggcaggtgagag 63
gagaaga agtggtgatgagtgggggga 63.6
ggagga ggggagagagagagaggtca 61
taactt atggagatagttggtctcag 57.5
gggggc ctgcttttggacccctcttt 63
tttttc cctccatgacttgacagc 62
ccacac gcagggttgttgggaagagt 63
tttcaag ctgccttcccatgtctggtc 63
gggcaca ggctgctattttgtctatgg 63
gaatcc ctcagaaccttgggagaatc 62
tgct ggagtaggggatgaacaag 63
cttttc gtaggtagggagatgtcct 61.5
ccagga gcagatcccattcccatcag 64
gactc tacaacaggaaaagcatcaga 62
ccc agcctgggcctcagagaa 64.5
tttca ggtggaagagccaacagta 63
tccct gggtcaaggtcagtatggtc 62
ccttga gccccacaactctcaatct 61.5
tct ggctgcgtgaggttgttg 63
ctta acagaaccagcccaggga 62.5
taga acatggacagaaagggga 62.5, 69.5
ctct gaggctggagtggctcag 63.5
aggag tccttgcttgggccaggt 63
tgctt gcctcagccagaagtcag 66
cct ctggcctctcactgaacc 64.5
agtga cccttgggtggcaccata 63
aact gggatgagaacagggacc 63
ctgc ggcaggaggaatctggtg 65
tcc cagcctgtgctcccttca 66.5
gcaa agcccacggagagacact 62
tgtgt gccctggaagaggctaag 65.5
acctt ctcccctgggcctagtc 63.7
tctga gggtttgagggtgctctg 64.5
tacc ggtcctcagggcagtgaa 60.5
30 s; and 72°C for 10 min. PCR method 2  94°C for 5 min; 5 cycles of 94°C for
or 30 s; and 72°C for 10 min. PCR method 3  94°C for 10 min; 40 cycles of 94°C
chain reaction.Meth
d Pri
uenc
aagaa
gagga
aagtca
tgacct
ggcttc
ggagg
actggt
aaccc
gagcc
tacttc
gaacca
agagt
tggac
gagca
actga
ttcttta
caaag
tgggt
ctcttt
cactcc
tctcct
atgga
cttctc
tctcc
gccttt
ttgcac
tagag
ggggt
ccaca
tgaag
ccctcc
actgt
tcctga
cagcaa
gcaag
atgct
aggag
cccaa
°C for
72°C f719Q mutation had a second mutation in MYH7, perhaps
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utation and the patient’s clinical course.
Among the 58 HCM patients with MYH7, two harbored
ultiple mutations. One patient had two MYH7 mutations:
719Q and T1513S. This 28-year-old female was diag-
osed at age 13 years. She experienced syncopal events at
ge 12 and 19 years. At age 25, she developed symptoms of
atigue and exertional dyspnea, which were treated with
eta-blocker therapy. At age 26, an implantable
able 2. Clinical Characteristics of Hypertrophic Cardiomyopath
All Patients
(n  389)
ale/female 215/174
ge at diagnosis (yrs)
Mean 41.3  19
Range 0–89.5
25 yrs 81 (21%)
resentation
Cardiac symptoms (NYHA class II to IV) 216 (56%)
amily history*
HCM 120 (31%)
SCD 56 (14%)
chocardiography
LVWT (mm) 21.6  6
Severe hypertrophy† 29 (7%)
Peak LVOT gradient (mm Hg) 46.6  42
LVOT 30 mm Hg at rest 206 (53%)
reatment
Myectomy 161 (41%)
PM 68 (17%)
Myectomy or PM 190 (49%)
ICD 60 (15%)
In a first-degree relative. †LVWT 30 mm. ‡Minnesota, Wisconsin, and Iowa res
ICD  implantable cardioverter-defibrillator; HCM  hypertrophic cardiomyopa
not significant; NYHA  New York Heart Association; PM  permanent pacem
able 3. Clinical Characteristics of Hypertrophic Cardiomyopath
MYH7
(n  58)
ale/female 26/32
ge at diagnosis (yrs)
Mean 32.9  18
Range 0.1–70.6
25 yrs 20 (34%)
resentation
Cardiac symptoms (NYHA class II to IV) 31 (54%)
amily history*
HCM 25 (43%)
SCD 9 (16%)
chocardiography
LVWT (mm) 24.1  8
Severe hypertrophy† 9 (16%)
Peak LVOT gradient (mm Hg) 53.6  46
LVOT 30 mm Hg at rest 36 (62%)
reatment
Myectomy 35 (60%)
PM 12 (21%)
Myectomy or PM 37 (64%)
ICD 13 (22%)
In a first-degree relative. †LVWT 30 mm. ‡Minnesota, Wisconsin, and Iowa res
Abbreviations as in Table 2.ardioverter-defibrillator (ICD) was placed as primary pre-
ention for SCD partly because of a family history of SCD
nvolving four relatives: her mother (age 36 years), maternal
ousin (age 15 years), maternal grandmother (age 28 years),
nd maternal great-grandmother.
In a second patient, a novel intronic G1A substitution
receding exon 12 of troponin T is present, as well as the
453C-MYH7 mutation. Tissue analysis demonstrates that
he TNNT2 mutation causes alternative splicing, resulting
ient Cohort
egional‡
n  125)
Nonregional
(n  264)
p Value
(Regional vs. Nonregional)
70/55 145/119 NS
1.9  20 41.0  18 NS
0–84.2 0.1–89.5 —
30 (24%) 50 (19%) NS
60 (48%) 156 (63%) NS
44 (35%) 76 (29%) NS
21 (17%) 35 (13%) NS
1.5  7 21.6  6 NS
10 (8%) 19 (7%) NS
9.1  40 50.0  43 0.02
60 (48%) 146 (55%) NS
35 (28%) 126 (48%) 0.01
24 (19%) 44 (17%) NS
49 (40%) 141 (53%) 0.01
26 (21%) 34 (13%) 0.04
. Data are presented as the number (%) of subjects or mean value  SD.
VOT  left ventricular outflow tract; LVWT  left ventricular wall thickness; NS
SCD  sudden cardiac death.
ients With the MYH7 Gene
-MYH7
331)
p Value
MYH7 vs.
Non-MYH7
MYH7
Regional‡
(n  20)
MYH7
Nonregional
(n  38)
9/142 NS 10/10 16/22
 18 0.0002 37.1  19 30.8  17
89.5 — 5.9–68.4 0.1–70.6
(18%) 0.006 6 (30%) 14 (37%)
(56%) NS 14 (70%) 17 (45%)
(29%) 0.006 9 (45%) 16 (42%)
(14%) NS 4 (20%) 5 (13%)
 6 0.0009 22.7  7 24.9  9
(6%) 0.01 1 (5%) 8 (21%)
 42 NS 52.8  47 54.1  46
(51%) NS 12 (60%) 24 (63%)
(38%) 0.002 10 (50%) 25 (66%)
(17%) NS 4 (20%) 8 (21%)
(46%) 0.01 12 (60%) 25 (66%)
(14%) NS 5 (25%) 8 (21%)
. Data are presented as the number (%) of subjects or mean value  SD.y Pat
R
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42.7
0–
61
185
95
47
21.1
20
45.1
170
126
56
153
47
idents
i
n
e
y
p
m
c
a
e
h
o
d
t
F
r
m
n
606 Van Driest et al. JACC Vol. 44, No. 3, 2004
Beta-Myosin Heavy Chain Mutations in HCM August 4, 2004:602–10n an in-frame deletion of Q191 at the protein level (data
ot shown). This patient was diagnosed during infancy after
valuation of a murmur and underwent myectomy at age 11
ears for severe hypertrophy (38 mm septum). An ICD was
laced after an episode of ventricular tachycardia two
onths later.
Of the 40 mutations, 33 (83%) occurred just once within the
igure 1. Distribution of mutations in the MYH7 gene. In the schematic di
epresent untranslated regions. Mutations identified in this cohort are id
utations found in more than one individual in the cohort, the mutation
ot found in this cohort are identified below the exons (11).ohort. The majority of HCM patients with MYH7 had
lterations within the functional head and neck domains
ncoded by exons 3 through 23, but 12 (21%) of 58 patients
ad mutations affecting the rod portion (exons 24 through 40)
f the protein. However, there was no difference in phenotype
etected between the subset of patients with rod mutations and
hose with head and neck mutations (data not shown).
, vertical lines symbolize the exons of the gene and unfilled vertical lines
d above the exons. *  a novel, not previously published mutation. For
ency is indicated in parentheses. All previously reported exonic mutationsagram
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August 4, 2004:602–10 Beta-Myosin Heavy Chain Mutations in HCMRecent data have suggested that mutations altering the
harge of amino acids within critical functional domains are
ssociated with a more severe disease phenotype than
eutral substitutions (non-charge changing) or those alter-
ng residues outside of critical domains (23). In this cohort,
comparison between patients with mutations affecting any
unctional domain of the MYH7 protein (as assigned by
23,24]) and those patients with mutations occurring out-
ide these functional domains revealed no statistically sig-
ificant difference in any variable (data not shown). Patients
ith charge-changing MYH7 mutations had a trend toward
younger age at diagnosis (28.2  18 years vs. 37.2  17
ears, p  0.058) than patients with neutral substitutions.
ithin the subset of patients harboring mutations in a
unctional domain, those with charge-changing substitu-
ions were not statistically different from those with neutral
ubstitutions for any clinical variable. However, patients
ith charge-changing mutations in a functional domain
ere significantly younger at diagnosis than those patients
ith neutral substitutions outside a functional domain (20.7
17 years vs. 38.6  18 years, p  0.018).
In addition to the 40 mutations identified, 21 silent
olymorphisms were identified, and two nonsynonymous
olymorphisms (S1491C and K1919N) were present in
oth patient samples and the reference alleles (Table 4).
wenty-six sequence variants were defined in the intronic
equences flanking the exons. Overall, sequence variations
ere identified in 33 of the 38 amplicons analyzed, and of
he 5 exons where no variants were found, 4 have no
reviously published HCM-causing mutations.
ISCUSSION
henotype of MYH7-HCM. This study represents a com-
rehensive analysis of the entire protein-coding region of
YH7 in the largest cohort of unrelated HCM patients (n
389) published to date. Here, at a tertiary referral center
pecializing in the diagnosis and surgical treatment of
CM, 15% of HCM patients harbored a MYH7 mutation.
he subset of HCM patients with MYH7 mutations was
ounger at diagnosis and had more hypertrophy than HCM
atients without MYH7 mutations. The HCM patients
ith MYH7 also had a higher frequency of a family history
f HCM in a first-degree relative, consistent with increased
enetrance. However, these patients had no higher inci-
ence of SCD events in first-degree relatives. Therefore, our
ata support the conventional wisdom that patients with
YH7 mutations are more likely to manifest the disease
penetrance) and confirm the key observation that patients
ith MYH7 mutations appear more susceptible to greater
ypertrophy than the rest of a genetically heterogeneous
ohort (8,12). More importantly, however, we were unable
o demonstrate that individuals with MYH7-HCM were
ore vulnerable to sudden death than those patients with
ny other pathogenic basis for their HCM.
Consistent with our previous findings regarding “malig-ant” and “benign” MYH7 mutations, patients with “malig-
ant” mutations were diagnosed at a young age but were not
therwise different from the cohort (20). Patients with
benign” mutations had significant manifestations of dis-
ase, including a young age at diagnosis and a family history
f SCD (22). These data indicate that the prognostic value
f any particular mutation, as determined by disease pre-
entation in an unrelated family, may not be an accurate
uide for risk assessment.
able 4. Polymorphisms Identified
Exon DNA Change Amino Acid Position
3 accact T63T*
4 tactat Y109Y
4 aacaat N107N
4 ccccct P99P
5 gtggta V139V
7 gcagcg A199A
7 ga at intron  50 —
8 ga at intron  17 —
11 gacgat D325D
11 tactat Y308Y
11 tc at intron  43 —
12 aagaaa K364K
12 gacgat D376D
12 ggcggt G354G
13 gt at intron  52 —
14 gt at intron  57 —
16 ctgcta L557L
16 gaagag E535E
16 aacaat N589N
18 at at intron  39 —
18 ag at intron  57 —
19 ac at intron  17 —
19 ga at intron  20 —
19 ga at intron  29 —
21 ga at intron  20 —
22 agtagc S842S
22 cg at intron  7 —
24 attatc I989I*
24 ga at intron  18 —
25 gcggca A1051A
28 ct at intron  21 —
29 ga at intron  16 —
30 ga at intron  30 —
31 ga at intron  42 —
32 ctcctt L1484L
32 tcctgc S1491C*
32 ac at intron  43 —
33 accact T1522T*
33 ct at intron  24 —
34 cggcga R1560R
35 gcggag A1702A
36 ct at intron  19 —
36 ct at intron  35 —
38 ga at intron  32 —
38 tg at intron  15 —
38 ag at intron  16 —
39 aagaac K1919N
40 ga at 5UTR  111 —
40 gt at 5UTR  20 —
Previously published polymorphism. Non-synonymous variants are denoted in bold.Importantly, the design of this study differs from previous
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Beta-Myosin Heavy Chain Mutations in HCM August 4, 2004:602–10enotype-phenotype correlations in that we included only
ne member from each affected family. This study design,
sing a large cohort of genetically independent patients, is
ecessary to determine whether the insights provided by
revious studies of large pedigrees can be applied to indi-
idual patients in the clinician’s office. Our data indicate
hat MYH7 mutations are associated with greater hypertro-
hy and younger age at diagnosis, which may assist in
argeted gene screening. Identification of the pathogenic
utation will aid in preclinical diagnosis and genetic coun-
eling; however, the MYH7 mutation status should not be
onsidered a primary risk factor for SCD.
nalysis of the tertiary referral center cohort. This co-
ort of 389 unrelated patients represents a biased sample of
he population of patients with HCM. Because these
atients were recruited from a tertiary referral center with
nown expertise in the surgical management of HCM,
atients with significant obstruction and symptomatic pre-
entation are over-represented, as evidenced by the compar-
son of regional versus non-regional patient subsets.
However, the frequency of MYH7 mutations identified in
hese subsets was not significantly different (16% in regional
nd 14% in non-regional), and there was no significant
ifference in any clinical parameter studied between the
egional and non-regional patients who had an identifiable
utation in the MYH7 gene. Therefore, the frequency of
utations and clinical correlations identified herein cannot
e attributed solely to a referral bias in this patient popula-
ion.
revalence of thick-filament HCM. Previous reports
ave speculated that 30% of all HCM cases are due to
utations in MYH7, the largest of 10 HCM-associated
enes encoding the thick and thin filaments of the sarco-
ere (10). Previously, a study examining MYH7 in 36
nrelated Finnish patients determined that only 2 patients
5.6%) had MYH7 mutations (25). In contrast, a recent
omprehensive analysis of 197 unrelated patients from
rance revealed that 25% had MYH7 mutations (15). Here,
n the largest published cohort, we found that 15% of
atients harbored mutations in MYH7.
The accuracy of this estimate of MYH7 mutation fre-
uency in HCM is dependent on several issues. Foremost is
he sensitivity of our mutation detection platform—
HPLC. It is possible that additional MYH7 mutations
luded detection. However, the published sensitivity for
HPLC has been established in multiple applications at
95%, and sensitivity of 100% has been reported for HCM
utation screening (26–29). In our own quality-control
xperiments of our optimization methods and DHPLC
ensitivity using direct sequencing as a gold standard, our
utation detection sensitivity was found to be 100% (data
ot shown). Therefore, it is unlikely that mutations were
issed.
Second, it is possible that mutations identified represent
are polymorphisms and are not pathogenic for HCM. It is
or this reason that both the Caucasian reference alleles, hhich are ethnically matched for the vast majority of our
ohort, and the African-American reference alleles, which
ave been observed to have greater diversity of polymor-
hisms, were both utilized. In addition, the MYH7 protein
as only two variable amino acid residues identified to date
including one identified herein), despite rigorous study of
he gene since its discovery in 1990 as the sentinel genetic
ause of HCM. Therefore, it is most likely that the
utations identified are indeed pathogenic.
Finally, if clinical evaluation of relatedness failed to
iscern distantly related individuals, founder effects may
kew the reported mutation frequency from the true muta-
ion rate. However, given that 83% of the identified MYH7
utations occurred only once in the cohort, the effects
ould be negligible.
pectrum of mutations in the thick filament. It has been
uggested that because the globular head and neck regions
f the MYH7 protein directly affect motor function, muta-
ions will be clustered within these domains, encoded by
xons 3 through 23 (14,24). The head contains the actin and
denosine triphosphate-binding regions that are responsible
or the force generation properties of myosin. The neck
ends as the globular head is displaced throughout the
ower stroke. Over 80 missense mutations have been
reviously identified in exons 3 through 23, which encode
or the head and neck domains (11). In our cohort, 79% of
he HCM patients with MYH7 had mutations residing in
he head and neck domains.
There have been only eight mutations previously reported
n the rod portion of MYH7 (encoded by exons 24 through
0) (15,30), but these mutations were reported to account
or up to 20% of MYH7-HCM (30). In this study, we report
mutations (8 novel) affecting the rod domain in 12
atients. Provided these mutations prove to be pathogenic
or HCM, rod mutations account for one-fifth of our HCM
atients with MYH7 mutations. Given that the rod portion
f MYH7 has been less well characterized than the head
omain, with respect to nonpathogenic single-nucleotide
olymorphisms (SNPs), it is possible that these mutations
n the rod represent irrelevant SNPs, disease modifiers, or
NPs linked to mutations in a neighboring gene. All but the
ast may be determined by future linkage studies of the
ffected families. In discerning SNPs linked to the true
enetic substrates for disease, high-throughput sequence
nalysis of even larger cohorts of healthy individuals will
rovide additional data on the prevalence and spectrum of
onpathogenic MYH7 variants. Interestingly, however, the
atients with putative rod-domain mutations presented
ith a clinical phenotype indistinguishable from those with
utations involving the head and neck of MYH7. There-
ore, genetic testing of MYH7 should include analysis of
xons 24 through 40 that encode the rod domain.
Our analysis identified two mutational “hot spots.” Nine
15%) of the 58 HCM patients with MYH7 harbored
utations at amino acid 663 (exon 18), and 4 (7%) of 58ad mutations at amino acid 1377 (exon 30). Although
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August 4, 2004:602–10 Beta-Myosin Heavy Chain Mutations in HCMreviously published as HCM-causing mutations (15), 400
eference alleles were analyzed to exclude these variants as
ommon polymorphisms present in the unaffected popula-
ion. The previously published L908V mutation was also
dentified in four unrelated patients.
iversity of thick-filament mutations. Prior to this study,
here were 95 cited MYH7 mutations (11). In this study, 40
ifferent mutations were identified, 25 (63%) of which were
ovel. Thirty-three (83%) of the 40 mutations had a single
ncidence within the cohort. This substantial degree of
ovelty and uniqueness further supports the genetic heter-
geneity of HCM and has implications for the future of
enetic testing as a diagnostic tool. Using current technol-
gy, it will be difficult and prohibitively expensive to screen
or HCM-causing mutations as a clinical test because of the
verall low occurrence of sarcomeric mutations and the high
ncidence of novel and unique mutations. In addition,
ompilation of sufficient (statistically significant) HCM
henotype data for unrelated individuals with the same
athogenic mutation for meaningful risk stratification may
ot be achievable in this highly diverse disease. By grouping
utations by functional domain and effect on amino acid
harge, a method previously reported to discern statistically
ignificant differences in phenotype (25), some statistically
ignificant variables did emerge. Future analysis of even
arger patient groups may determine that mutation location
n the protein and the effect on charge can assist in the
rediction of clinical severity among unrelated patients.
ompound heterogeneity in HCM. Of the 58 patients
dentified with thick-filament HCM, two were found to
ave multiple sarcomeric mutations, and each has experi-
nced a severe clinical course. These two cases with multiple
utations highlight the potential for compound heterozy-
osity, heterozygous synergism, and/or genetic disease mod-
fiers in HCM. Specifically, the incidence of multiple
arcomeric mutations in HCM patients may be higher than
ould be estimated by analysis of the current literature, as
omprehensive screening of sarcomeric genes in large co-
orts of patients has only recently become technically
easible. Interestingly, each of these patients harbors a
utation previously characterized as “benign” or “malig-
ant” based on family studies (20,22). For these specific
atients, their status as carriers of multiple mutations may
utweigh any prognostic effect of their “benign” or “malig-
ant” mutation.
In one analysis of 197 patients with HCM for mutations
n nine genes, six families (3%) were identified as having
ultiple mutations (15). As in this study, more rigorous
nalysis of these families is required to determine the role of
ach individual mutation and the effect of multiple sarco-
eric defects. The effects of multiple mutations on disease
everity may contribute to the variability seen within fami-
ies and in unrelated individuals sharing the identical patho-
enic mutation.
onclusions. The results of this study suggest that some ofhe findings from previous linkage studies may not apply tohe population of patients seen in clinical practice, although
he previous findings of more severe hypertrophy, younger
ge at diagnosis, and greater disease penetrance are sup-
orted by these data from an unrelated cohort. The fre-
uency of MYH7 mutations in the population of patients
ith HCM may be lower than previously suggested. Im-
ortantly, MYH7 mutations conferred no increased inci-
ence of SCD compared with HCM due to other genetic
auses. The clinical utility and applications of genetic
nalysis in HCM must continue to be explored to determine
he place of pathogenomics in the diagnosis, risk stratifica-
ion, and treatment of HCM.
cknowledgments
e are indebted to the HCM patients for their participa-
ion in this study. We thank Dr. Rick Nishimura, director
f Mayo’s HCM Clinic, for his critical reading of the
anuscript, as well as Mr. Doug Kocer, Nurse Coordinator
or the HCM Clinic. We appreciate the technical assistance
rovided by David J. Tester and Sonja Eichmuller.
eprint requests and correspondence: Dr. Michael J. Ackerman,
udden Death Genomics Laboratory, Guggenheim 501, Mayo
linic, Rochester, Minnesota 55905. E-mail: ackerman.michael@
ayo.edu.
EFERENCES
1. Maron BJ, Gardin JM, Flack JM, Gidding SS, Kurosaki TT, Bild DE.
Prevalence of hypertrophic cardiomyopathy in a general population of
young adults: echocardiographic analysis of 4111 subjects in the
Coronary Artery Risk Development In (young) Adults (CARDIA)
study. Circulation 1995;92:785–9.
2. Maron BJ. Hypertrophic cardiomyopathy: a systematic review. JAMA
2002;287:1308–20.
3. Maron BJ, Carney KP, Lever HM, et al. Relationship of race to
sudden cardiac death in competitive athletes with hypertrophic car-
diomyopathy. J Am Coll Cardiol 2003;41:974–80.
4. Arad M, Seidman JG, Seidman CE. Phenotypic diversity in hyper-
trophic cardiomyopathy. Hum Mol Genet 2002;11:2499–506.
5. Maron BJ, Bonow RO, Cannon RO, Leon MB, Epstein SE. Hyper-
trophic cardiomyopathy: interrelations of clinical manifestations,
pathophysiology, and therapy. N Engl J Med 1987;316:780–9.
6. Spirito P, Seidman CE, McKenna WJ, Maron BJ. The management
of hypertrophic cardiomyopathy. N Engl J Med 1997;336:775–85.
7. Seidman JG, Seidman C. The genetic basis for cardiomyopathy: from
mutation identification to mechanistic paradigms. Cell 2001;104:557–67.
8. Burch M, Blair E. The inheritance of hypertrophic cardiomyopathy.
Pediatr Cardiol 1999;20:313–6.
9. Roberts R, Sigwart U. New concepts in hypertrophic cardiomyopa-
thies, part I. Circulation 2001;104:2113–6.
0. Seidman CE, Seidman JG. Molecular genetic studies of familial
hypertrophic cardiomyopathy. Basic Res Cardiol 1998;93:13–6.
1. The FHC Mutation Database, ANGIS 2001. Available at: http://
morgan.angis.su.oz.au/Databases/Heart/dbsearch.html. Accessed
March 16, 2004.
2. Marian AJ, Roberts R. Molecular genetic basis of hypertrophic
cardiomyopathy: genetic markers for sudden cardiac death. J Cardio-
vasc Electrophysiol 1998;9:88–99.
3. Fananapazir L, Dalakas MC, Cyran F, Cohn G, Epstein ND.
Missense mutations in the beta-myosin heavy-chain gene cause central
core disease in hypertrophic cardiomyopathy. Proc Natl Acad Sci USA
1993;90:3993–7.
4. Watkins H, Rosenzweig A, Hwang DS, et al. Characteristics and
prognostic implications of myosin missense mutations in familial
hypertrophic cardiomyopathy. N Engl J Med 1992;326:1108–14.
11
1
1
1
2
2
2
2
2
2
2
2
2
2
3
610 Van Driest et al. JACC Vol. 44, No. 3, 2004
Beta-Myosin Heavy Chain Mutations in HCM August 4, 2004:602–105. Richard P, Charron P, Carrier L, et al. Hypertrophic cardiomyopathy:
distribution of disease genes, spectrum of mutations, and implications
for a molecular diagnosis strategy. Circulation 2003;107:2227–32.
6. Antonarakis SE, and the Nomenclature Working Group. Recommen-
dations for a nomenclature system for human gene mutations. Hum
Mutat 1998;11:1–3.
7. Van Driest SV, Ellsworth EG, Ommen SR, Tajik AJ, Gersh BJ,
Ackerman MJ. Prevalence and spectrum of thin filament mutations in
an outpatient referral population with hypertrophic cardiomyopathy.
Circulation 2003;108:445–51.
8. Towbin JA. Molecular genetic basis of sudden cardiac death. Cardio-
vasc Pathol 2001;10:283–95.
9. Hwang T, Lee W, Kimura A, et al. Early expression of a malignant
phenotype of familial hypertrophic cardiomyopathy associated with a
Gly716Arg myosin heavy chain mutation in a Korean family. Am J
Cardiol 1998;82:1509–13.
0. Ackerman MJ, Van Driest SV, Ommen SR, et al. Prevalence and
age-dependence of malignant mutations in the beta-myosin heavy
chain and troponin T gene in hypertrophic cardiomyopathy: a com-
prehensive outpatient perspective. J Am Coll Cardiol 2002;39:2042–8.
1. Consevage MW, Salada GC, Baylen BG, Ladda RL, Rogan PK. A
new missense mutation, Arg719Gln, in the beta-cardiac heavy chain
myosin gene of patients with familial hypertrophic cardiomyopathy.
Hum Mol Genet 1994;3:1025–6.
2. Van Driest SV, Ackerman MJ, Ommen SR, et al. Prevalence and
severity of ‘benign’ mutations in the beta myosin heavy chain, cardiac
troponin-T, and alpha tropomyosin genes in hypertrophic cardiomy-
opathy. Circulation 2002;106:3085–90.3. Woo A, Rakowski H, Liew JC, et al. Mutations of the beta myosin
heavy chain gene in hypertrophic cardiomyopathy: critical functional
sites determine prognosis. Heart 2003;89:1179–85.
4. Rayment I, Holden HM, Sellers JR, Fananapazir L, Epstien ND.
Structural interpretation of the mutations in the beta-cardiac myosin
that have been implicated in familial hypertrophic cardiomyopathy.
Proc Natl Acad Sci USA 1995;92:3864–8.
5. Jaaskelainen P, Soranta M, Miettinen R, et al. The cardiac beta-
myosin heavy chain gene is not the predominant gene for hypertrophic
cardiomyopathy in the Finnish population. J Am Coll Cardiol 1998;
32:1709–16.
6. Xiao W, Oefner P. Denaturing high-performance liquid chromatog-
raphy: a review. Hum Mutat 2001;17:439–74.
7. Schollen E, Martens K, Geuzens E, Matthijs G. DHPLC analysis as
a platform for molecular diagnosis of congenital disorders of glycosyl-
ation (CDG). Eur J Hum Genet 2002;10:643–8.
8. Young J, Barker M, Fraser L, et al. Mutation searching in colorectal
cancer studies: experience with a denaturing high-pressure liquid
chromatography system for exon-by-exon scanning of tumour suppres-
sor genes. Pathology 2002;34:529–33.
9. Mogensen J, Bahl A, Kubo T, Elanko N, Taylor R, McKenna WJ.
Comparison of fluorescent SSCP and denaturing HPLC analysis with
direct sequencing for mutation screening in hypertrophic cardiomyop-
athy. J Med Genet 2003;40:1–5.
0. Blair E, Redwood C, de Jesus Oliveira M, et al. Mutations of the light
meromyosin domain of the beta-myosin heavy chain rod in hypertro-
phic cardiomyopathy. Circ Res 2002;90:263–9.
